Mirae Asset Global Investments Co. Ltd. Acquires 40,283 Shares of Novo Nordisk A/S $NVO

Key Points

• Mirae Asset increased its stake in Novo Nordisk by 8.7%, buying 40,283 shares to hold 503,078 shares valued at about $25.6 million at the end of the quarter.
• Novo is showing competitive strength in the GLP‑1/weight‑loss market—benefiting from a modest Eli Lilly launch and early data favoring semaglutide—while longer‑term risks include generic semaglutide competition and sectorwide healthcare weakness.
• Analysts maintain a consensus "Hold" on NVO with an average price target of $65.56; the company recently beat quarterly expectations (EPS $1.01 vs. $0.90 consensus and revenue $12.43B vs. $11.97B).

Mirae Asset Global Investments Co. Ltd. boosted its holdings in Novo Nordisk A/S (NYSE:NVO - Free Report) by 8.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 503,078 shares of the company's stock after purchasing an additional 40,283 shares during the quarter. Mirae Asset Global Investments Co. Ltd.'s holdings in Novo Nordisk A/S were worth $25,597,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. True Wealth Design LLC increased its holdings in Novo Nordisk A/S by 209.8% in the third quarter. True Wealth Design LLC now owns 443 shares of the company's stock worth $25,000 after purchasing an additional 300 shares in the last quarter. Guerra Advisors Inc bought a new stake in shares of Novo Nordisk A/S during the third quarter valued at approximately $25,000. American National Bank & Trust bought a new stake in shares of Novo Nordisk A/S during the fourth quarter valued at approximately $28,000. Maseco LLP bought a new stake in shares of Novo Nordisk A/S during the fourth quarter valued at approximately $29,000. Finally, Strengthening Families & Communities LLC bought a new stake in shares of Novo Nordisk A/S during the third quarter valued at approximately $30,000. 11.54% of the stock is currently owned by institutional investors.

More Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo benefits from a modest U.S. launch for Eli Lilly’s new oral obesity pill, which recorded only 1,390 prescriptions in its debut week — a slow start that helps preserve Novo’s lead in the GLP-1/weight-loss market. Novo Nordisk Extends Lead As Eli Lilly New Obesity Pill Sees Modest Launch Uptake
• Positive Sentiment: A new pre-peer-review study suggests Novo’s semaglutide preserves lean body mass better than Lilly’s tirzepatide, supporting a potential clinical differentiation that could influence physician prescribing and payor decisions. Novo weight-loss drug may preserve lean body mass better than Lilly's, study finds
• Positive Sentiment: The FDA requested additional safety data from Lilly on its Foundayo launch, a near-term regulatory hiccup for Lilly that can indirectly help Novo by slowing competitor momentum. Lilly Stock Dips on FDA Request for More Foundayo Safety Data
• Positive Sentiment: Company capacity is expanding: reports say Novo Nordisk has added ~2,000 staffers this year, signaling preparation for continued demand and commercialization scale-up. Novo Nordisk has reportedly added 2,000 to workforce this year
• Neutral Sentiment: Analyst coverage continues to include Novo among large-cap health names highlighted by Zacks — attention is positive for liquidity but not an immediate catalyst. The Zacks Analyst Blog Highlights Netflix, PepsiCo, Novo Nordisk
• Neutral Sentiment: Big biotech financing continues: Kailera’s large IPO shows investor interest and capital flow into obesity drug developers — increases sector activity but not an immediate threat to Novo’s franchise. Kailera nets $625M in one of biotech’s biggest-ever IPOs
• Negative Sentiment: Generics pressure: Hetero Labs aims to roll out 1.5M generic semaglutide pens annually as it expands globally — a longer-term pricing and share risk for Novo in certain markets. Indian's Hetero targets annual sales of 1.5 million semaglutide pens in global rollout
• Negative Sentiment: Sector-wide weakness in healthcare equities is creating downward pressure on peer stocks, which can amplify short-term moves in Novo’s share price despite company-specific positives. Sector Update: Health Care Stocks Lower in Afternoon Trading

Analyst Ratings Changes

NVO has been the subject of several recent research reports. TD Cowen downgraded Novo Nordisk A/S from a "buy" rating to a "hold" rating and set a $42.00 price objective for the company. in a report on Tuesday, March 10th. Jefferies Financial Group upgraded Novo Nordisk A/S from an "underperform" rating to a "hold" rating in a report on Thursday, February 12th. Kepler Capital Markets downgraded Novo Nordisk A/S from a "buy" rating to a "hold" rating in a report on Tuesday, February 24th. Zacks Research upgraded Novo Nordisk A/S from a "strong sell" rating to a "hold" rating in a report on Tuesday, March 10th. Finally, Weiss Ratings upgraded Novo Nordisk A/S from a "sell (d+)" rating to a "hold (c-)" rating in a report on Tuesday, April 7th. Four analysts have rated the stock with a Buy rating and nineteen have given a Hold rating to the stock. According to data from MarketBeat.com, Novo Nordisk A/S currently has a consensus rating of "Hold" and an average price target of $65.56.

Novo Nordisk A/S Trading Down 1.1%

Shares of Novo Nordisk A/S stock opened at $40.47 on Friday. The stock has a fifty day simple moving average of $40.07 and a 200 day simple moving average of $48.46. Novo Nordisk A/S has a 12-month low of $35.12 and a 12-month high of $81.44. The company has a market capitalization of $180.72 billion, a P/E ratio of 11.66, a price-to-earnings-growth ratio of 9.65 and a beta of 0.73. The company has a current ratio of 0.80, a quick ratio of 0.57 and a debt-to-equity ratio of 0.61.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its quarterly earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.90 by $0.11. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%.The business had revenue of $12.43 billion during the quarter, compared to the consensus estimate of $11.97 billion. On average, sell-side analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Announces Dividend

The business also recently declared a dividend, which was paid on Wednesday, April 8th. Investors of record on Monday, March 30th were issued a dividend of $1.2751 per share. The ex-dividend date was Monday, March 30th. This represents a yield of 723.0%. Novo Nordisk A/S's dividend payout ratio is 50.43%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.